As shown by the analysis of AML-related gene mutation between high and low-risk groups (Figure 6A), the adverse-risk gene mutations such as TP53, SMC3 and PTPN11 mutations (26, 49, 50) have obviously higher frequency in high-risk group. This evidence concerns the gene TP53 and acute myeloid leukemia.